Markets:

Overview

News

Currencies

International

Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

0.9792 -0.0111 (-1.12%)

Delayed Quote Updated: 11:27 AM EST, Nov 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 Next >

Lineage (LCTX) Q3 2026 Earnings Call Transcript ↗

Today 11:13 EST

Lineage adds a Huntington's program and shifts its cash runway outlook.

Via The Motley Fool

Topics Earnings Intellectual Property

What Lineage Cell Therapeutics (LCTX) Said on Its Q3 Earnings Call ↗

Today 3:14 EST

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) has acquired privately held NeuroAirmid Therapeutics, adding an experimental Huntington’s disease cell therapy to its clinical pipeline as the company...

Via MarketBeat

Topics Earnings

Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

CEO outlines manufacturing scale-up strategy for cell therapies amid $50.8M cash runway.

Via The Motley Fool

Topics Earnings

Lineage Cell Therapeutics (NYSEARCA:LCTX) Slips on Q2 Revenue Miss, but EPS In Line and Pipeline Advances ↗

August 06, 2026

Via Chartmill

Lineage Cell Therapeutics (NYSEARCA:LCTX) Q1 2026 Results: Revenue Miss and Increased Losses Weigh on Investor Sentiment ↗

May 12, 2026

Via Chartmill

Lineage Cell Therapeutics (LCTX) Reports Q4 Revenue Beat and Narrowed Loss ↗

March 05, 2026

Via Chartmill

Lineage Cell Therapeutics Q2 Earnings Call Highlights ↗

August 09, 2026

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type...

Via MarketBeat

Topics Earnings

Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan ↗

July 14, 2026

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being...

Via MarketBeat

Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call ↗

July 01, 2026

On Tuesday, Lineage Cell Therapeutics (AMEX:LCTX) discussed first-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to...

Via Benzinga

Topics Earnings

Lineage Cell Therapeutics Q1 Earnings Call Highlights ↗

May 15, 2026

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program...

Via MarketBeat

Topics Earnings

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

A Peek at Lineage Cell Therapeutics's Future Earnings ↗

August 11, 2025

Via Benzinga

Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock ↗

March 11, 2025

Via Benzinga

Lineage Cell Therapeutics Inc (NYSEARCA:LCTX) Reports Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗

November 06, 2025

Lineage Cell Therapeutics reports Q3 2025 results with a revenue beat but a wider net loss. The company advances its cell therapy pipeline and has cash into 2027.

Via Chartmill

12 Health Care Stocks Moving In Monday's After-Market Session ↗

September 22, 2025

Via Benzinga

5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know ↗

August 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

August 15, 2025

Via Benzinga

Lineage Cell Revenue Doubles in Q2 ↗

August 12, 2025

Via The Motley Fool

Forecasting The Future: 6 Analyst Projections For Lineage Cell Therapeutics ↗

January 31, 2025

Via Benzinga

The Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 Experts ↗

January 03, 2025

Via Benzinga

Lineage Cell Therapeutics Inc. (NYSEARCA:LCTX) Reports Q2 2025 Revenue Beat but Wider Loss ↗

August 12, 2025

Lineage Cell Therapeutics Q2 2025: Revenue beats estimates at $2.77M (+84.6%), but net loss widens to -$0.13. Stock dips 4.95% amid clinical progress and cash runway into 2027.

Via Chartmill

Two Biotech Stocks Poised For Big Moves On Monday ↗

June 23, 2025

Via Benzinga

Examining the Future: Lineage Cell Therapeutics's Earnings Outlook ↗

May 12, 2025

Via Benzinga

Which stocks are moving after the closing bell on Wednesday? ↗

April 16, 2025

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 16, 2025

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 15, 2025

Via Benzinga

Earnings Scheduled For March 10, 2025 ↗

March 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 20, 2024

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.